Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

This publication has 79 references indexed in Scilit:

• Evidence for use of glatiramer acetate in multiple sclerosis
  The Lancet Neurology, 2005
• Evidence for use of glatiramer acetate in multiple sclerosis
  The Lancet Neurology, 2005
• Evidence for use of glatiramer acetate in multiple sclerosis
  The Lancet Neurology, 2005
• Lack of evidence for use of glatiramer acetate in multiple sclerosis
  The Lancet Neurology, 2004
• Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications
  Proceedings of the National Academy of Sciences, 2004
• Therapeutic vaccines in autoimmunity
  Proceedings of the National Academy of Sciences, 2004
• Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
  Multiple Sclerosis Journal, 2000
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
  Neurology, 1998
• Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis
  Proceedings of the National Academy of Sciences, 1997
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
  Neurology, 1995